Due to the rarity of this alteration, the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was evaluated in the Rare Oncology Agnostic Research (ROAR) trial, a basket study investigating dabrafenib plus trametinib in BRAF V600E-mutated rare cancers [33]. The gene discussed is BRAF; the disease is cancer.